Year : 2020 | Volume
: 31 | Issue : 4 | Page : 145--146
Oncology and lower urinary tract symptom: The important nonviral urological diseases in COVID-19 infection era
Stephen Shei-Dei Yang
Department of Urology, Taipei Tzu Chi Hospital, New Taipei; School of Medicine, Buddhist Tzu Chi University, Hualien, Taiwan
Stephen Shei-Dei Yang
Department of Urology, Taipei Tzu Chi Hospital, New Taipei
|How to cite this article:|
Yang SS. Oncology and lower urinary tract symptom: The important nonviral urological diseases in COVID-19 infection era.Urol Sci 2020;31:145-146
|How to cite this URL:|
Yang SS. Oncology and lower urinary tract symptom: The important nonviral urological diseases in COVID-19 infection era. Urol Sci [serial online] 2020 [cited 2020 Nov 28 ];31:145-146
Available from: https://www.e-urol-sci.com/text.asp?2020/31/4/145/290855
The pandemic infection of COVID-19 virus has affected lives in Asia and the world. Although most countries have controlled the infection, there are some recurrent local surges in many Asian countries. Life has to go on, so do our academic activities and cares for nonviral patients. Oncology and lower urinary tract symptom (LUTS) are two of the important nonviral urological diseases in the COVID-19 infection era.
In this issue, Pramod reviewed “Smoking History, Smoking Intensity, and Type of Cigarette as a Risk Factor of Bladder Cancer.” We have long battled with smoking and this review updates the current knowledge in the relationship between cigarette and bladder cancer.
Lien et al. summarized their experience “Comparing the Predictive Values of DAP and RENAL Scores for Long-Term Trifecta Outcomes in Robot-Assisted Partial Nephrectomy for Renal Cell Carcinoma.” The conclusion was that the DAP score is an easy and effective tool for predicting perioperative outcomes of robot-assisted partial nephrectomy, especially in Warm ischemic time (WIT) in 20 min. For a long time, prostate-specific antigen (PSA) and its derivative formula have been widely used to predict the biopsy positive rate of prostate cancer. Lin et al. compared all the used formulae related to PSA and reported “The value of prostate specific antigen age-volume (PSA-AV) score in predicting prostate cancer in Taiwan.” PSA-AV seemed to have better predictive value in Asia. Hung et al. reported “Initial prostate biopsy of grade group one: A study of pathological upgrade and biochemical recurrence after robotic-assisted laparoscopic radical prostatectomy.” They warned that the final pathology grading was underestimated in 76.7% of initial biopsy grade group one (GG1) and may influence the biochemical recurrence-free survival after robotic-assisted laparoscopic radical prostatectomy. Prostate volume <30 mL and PSAD ≥0.2 ng/mL 2, measured by either magnetic resonance imaging or transrectal ultrasonography, were significant predictive factors of biopsy GG1 upgrading. This message is useful at counseling patients for shared decision-making. Enhanced recovery after surgery (ERAS) protocol has been pushed in many fields of surgery. Radical cystectomy is one of the lengthiest stays in urological patients. If you suffered from this issue, you may learn from the report by Pramod et al., “Modified Enhanced Recovery After Surgery Protocol (ERAS) versus non-ERAS in Radical Cystectomy Surgery (Preliminary Study).”
The etiology of LUTS is multiple. Hyashi et al. did the “Assessment of intrapelvic blood flow with the penile brachial index (PBI) using a toe blood pressure cuff in Japanese patients with lower urinary tract symptoms” and found that PBI was an independent factor of LUTS. Reduced pelvic blood flow could be a significant factor inducing LUTS in males. Is there one medicine superior to the others in predicting the rate of trial without catheter (TWOC) in patients with acute urinary retention? Parikh et al. did a small scale of randomized controlled study looking at the “Comparison of the effects of tamsulosin, silodosin, and alfuzosin on catheter free trials after acute urinary retention due to benign prostatic hyperplasia: A prospective study.” The total TWOC rate was 63%, and there was no difference in the efficacy of tamsulosin, silodosin, and alfuzosin in catheter-free trials.